The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

The rescinded Biden-era orders include actions to boost the Affordable Care Act exchanges, coordinate the government’s ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The University of New Hampshire Franklin Pierce School of Law is expanding its focus on specialized legal education with the ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

The innovative MicroCNX® Nano Series connectors help maintain sterility in CGT processes using 1/8- or 1/16-inch tubing and ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...